Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02315417
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
gevokizumab, Placebo, gevokizumab open-label
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Coral Gables, Florida • North Miami Beach, Florida • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

A Study of RX-10045 in the Treatment of Dry Eye Disease

NCT01675570
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Vehicle for RX-10045
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional

Code of Respect (X-CoRe): Trial of a Multi-level Sexual Assault and Sexual Harassment Prevention Intervention for Active Duty Airmen

NCT06101056
View directory record Official record
Conditions
Sexual Assault, Sexual Harassment
Interventions
Junior Enlisted Component, Leadership Component, Social Marketing Campaign
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

NCT00973141
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183
View directory record Official record
Conditions
Colitis Ulcerative, Ulcerative Colitis
Interventions
MK-8690, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

NCT01265745
View directory record Official record
Conditions
Anthrax
Interventions
Normal Saline for Injection, MDX1303
Drug · Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 23, 2026, 1:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Acute Impact of Yoga-based Stretching on Inflammation and Its Resolution

NCT04444102
View directory record Official record
Conditions
Inflammation, Fascia; Inflammation, Musculoskeletal Pain, Lower Back Pain, Neck Pain
Interventions
Yoga-based stretching
Procedure
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
40 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

NCT05650645
View directory record Official record
Conditions
Tinnitus
Interventions
incobotulinum toxin A, Placebo-Saline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

NCT01684345
View directory record Official record
Conditions
Uveitis
Interventions
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individualized Assessment and Treatment for Alcoholism II

NCT03233802
View directory record Official record
Conditions
Alcoholism
Interventions
Individualized Assess & Treatment (IATP), Packaged Cognitive-Behavioral (PCBT), Case Management (CaseM)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional

Pars Healing on MRI

NCT07215845
View directory record Official record
Conditions
Pars Interarticularis Stress Fracture, Pars Interarticularis Stress Injury
Interventions
MRI
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior

NCT01801254
View directory record Official record
Conditions
Obesity, Type II Diabetes, Cardiovascular Disease, Health Behavior
Interventions
STRIDES, Sham Control
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 4 Interventional Results available

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

NCT03937999
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Bezlotoxumab
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Results available

Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis

NCT00953199
View directory record Official record
Conditions
Pancreatitis
Interventions
Lidocaine Hydrochloride, Normal Saline
Drug
Lead sponsor
Abraham Mathew MD
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 23, 2026, 1:26 AM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06778434
View directory record Official record
Conditions
Actinic Keratosis, Imipramine, Photodynamic Therapy
Interventions
Imipramine, Control Vehicle
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

NCT04410354
View directory record Official record
Conditions
COVID-19
Interventions
Merimepodib, Matching Placebo, Remdesivir
Drug
Lead sponsor
ViralClear Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
GLASSIA, methylprednisolone or equivalent steroid, Albumin
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Results available

HIRREM Hot Flashes Study

NCT03512002
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes, Menopause
Interventions
HIRREM, Continued Current Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

NCT00984802
View directory record Official record
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Cleansing Before Cesarean Delivery to Reduce Infection

NCT02495753
View directory record Official record
Conditions
Complications; Cesarean Section
Interventions
Vaginal Cleansing, Abdominal Cleansing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 23, 2026, 1:26 AM EDT